Compare IPCA Labs with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DR. REDDYS LAB - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DR. REDDYS LAB IPCA LABS/
DR. REDDYS LAB
 
P/E (TTM) x 22.6 21.7 104.4% View Chart
P/BV x 4.4 3.2 135.3% View Chart
Dividend Yield % 0.1 0.7 14.7%  

Financials

 IPCA LABS   DR. REDDYS LAB
EQUITY SHARE DATA
    IPCA LABS
Mar-18
DR. REDDYS LAB
Mar-19
IPCA LABS/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6952,875 24.2%   
Low Rs4001,888 21.2%   
Sales per share (Unadj.) Rs260.2930.2 28.0%  
Earnings per share (Unadj.) Rs19.0117.4 16.2%  
Cash flow per share (Unadj.) Rs33.1185.8 17.8%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.20.8 21.7%  
Book value per share (Unadj.) Rs213.0844.4 25.2%  
Shares outstanding (eoy) m126.20166.07 76.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.12.6 82.2%   
Avg P/E ratio x28.920.3 142.3%  
P/CF ratio (eoy) x16.612.8 129.2%  
Price / Book Value ratio x2.62.8 91.2%  
Dividend payout %5.317.0 30.9%   
Avg Mkt Cap Rs m69,120395,496 17.5%   
No. of employees `00013.322.0 60.3%   
Total wages/salary Rs m7,35933,562 21.9%   
Avg. sales/employee Rs Th2,477.47,032.8 35.2%   
Avg. wages/employee Rs Th555.21,527.9 36.3%   
Avg. net profit/employee Rs Th180.6887.7 20.3%   
INCOME DATA
Net Sales Rs m32,836154,482 21.3%  
Other income Rs m4183,375 12.4%   
Total revenues Rs m33,254157,857 21.1%   
Gross profit Rs m4,50531,782 14.2%  
Depreciation Rs m1,77711,348 15.7%   
Interest Rs m240889 27.0%   
Profit before tax Rs m2,90522,920 12.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5113,858 13.2%   
Profit after tax Rs m2,39419,500 12.3%  
Gross profit margin %13.720.6 66.7%  
Effective tax rate %17.616.8 104.5%   
Net profit margin %7.312.6 57.8%  
BALANCE SHEET DATA
Current assets Rs m19,455111,101 17.5%   
Current liabilities Rs m10,07658,973 17.1%   
Net working cap to sales %28.633.7 84.6%  
Current ratio x1.91.9 102.5%  
Inventory Days Days9879 123.4%  
Debtors Days Days6794 71.1%  
Net fixed assets Rs m20,260101,245 20.0%   
Share capital Rs m252830 30.4%   
"Free" reserves Rs m26,633139,406 19.1%   
Net worth Rs m26,886140,236 19.2%   
Long term debt Rs m2,34022,000 10.6%   
Total assets Rs m41,173224,656 18.3%  
Interest coverage x13.126.8 48.9%   
Debt to equity ratio x0.10.2 55.5%  
Sales to assets ratio x0.80.7 116.0%   
Return on assets %6.49.1 70.5%  
Return on equity %8.913.9 64.0%  
Return on capital %10.814.9 72.0%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64288,673 17.6%   
Fx outflow Rs m4,88419,104 25.6%   
Net fx Rs m10,75969,569 15.5%   
CASH FLOW
From Operations Rs m3,41128,704 11.9%  
From Investments Rs m-1,354-7,727 17.5%  
From Financial Activity Rs m-1,304-21,326 6.1%  
Net Cashflow Rs m753-314 -239.9%  

Share Holding

Indian Promoters % 45.9 25.5 180.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 5.4 211.1%  
FIIs % 25.3 35.3 71.7%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.4 15.3 113.7%  
Shareholders   36,892 75,885 48.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SHASUN PHARMA  CIPLA  ASTRAZENECA PHARMA  SUVEN LIFESCIENCES  STERLING BIOTECH  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Tata Steel & Bajaj Finance Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note, tracking gains in global peers. US President Donald Trump said he did not want war.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 18, 2019 12:35 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS